As the current therapeutic development of VSV-GP as either an oncolytic or cancer vaccine virus targets existing tumors, we next examined how the presence of a tumor influences antigen-specific CD8+ T cells and their effector subtype composition. The gene discussed is CD8A; the disease is cancer.